2,000 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Hurley Capital LLC

Hurley Capital LLC bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,000 shares of the biotechnology company’s stock, valued at approximately $68,000.

Several other large investors also recently modified their holdings of the company. Cerity Partners LLC increased its stake in Exelixis by 129.1% in the third quarter. Cerity Partners LLC now owns 27,994 shares of the biotechnology company’s stock valued at $726,000 after purchasing an additional 15,777 shares in the last quarter. FMR LLC increased its stake in Exelixis by 6.1% in the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after buying an additional 140,568 shares during the last quarter. Captrust Financial Advisors lifted its holdings in Exelixis by 4.0% during the third quarter. Captrust Financial Advisors now owns 35,430 shares of the biotechnology company’s stock worth $919,000 after acquiring an additional 1,368 shares during the period. Verition Fund Management LLC bought a new stake in shares of Exelixis during the 3rd quarter worth $1,225,000. Finally, Janus Henderson Group PLC raised its position in Exelixis by 1.0% in the third quarter. Janus Henderson Group PLC now owns 123,347 shares of the biotechnology company’s stock worth $3,200,000 after acquiring an additional 1,201 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the company. Royal Bank of Canada boosted their target price on Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, March 13th. Wells Fargo & Company downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target for the company. in a report on Monday, February 24th. BMO Capital Markets lowered Exelixis from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $36.00 to $40.00 in a report on Friday, December 20th. Piper Sandler increased their target price on Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Finally, Bank of America cut shares of Exelixis from a “buy” rating to a “neutral” rating and increased their price target for the company from $35.00 to $39.00 in a research report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and an average target price of $37.59.

Exelixis Stock Down 5.8 %

NASDAQ:EXEL opened at $34.57 on Friday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The stock has a market cap of $9.68 billion, a P/E ratio of 19.53, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The firm’s fifty day simple moving average is $35.90 and its 200 day simple moving average is $33.60.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the sale, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 in the last 90 days. Insiders own 2.85% of the company’s stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.